Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2010 - 2026)

Catalyst Pharmaceuticals has reported Accumulated Expenses for 17 years, with the latest figure at $125.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 29369.88% year-over-year to $125.2 million; the trailing twelve-month figure through Mar 2026 stood at $125.2 million (up 29369.88% YoY), and the FY2025 full-year result was $11.4 million, down 89.09% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $125.2 million, up from $11.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $125.2 million in Q1 2026, with the low at $425000.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $47.3 million across 5 years, with a median of $48.1 million in 2023.
• Annual changes were most pronounced in 2025 — Accumulated Expenses slumped 99.39% — and 2026, when it jumped 29369.88%.
• Catalyst Pharmaceuticals' Accumulated Expenses stood at $53.6 million in 2022, then advanced by 14.28% to $61.3 million in 2023, then soared by 69.88% to $104.1 million in 2024, then plunged by 89.09% to $11.4 million in 2025, then jumped by 1002.72% to $125.2 million in 2026.
• The last three Accumulated Expenses figures came in at $125.2 million (Q1 2026), $11.4 million (Q4 2025), and $119.6 million (Q3 2025), per Business Quant data.